Treatment-Refractory Advanced Urothelial Cancer: What to Do After Chemotherapy and/or Immunotherapy

Download slides by Arjun Balar, MD on the role of antibody-drug conjugates in advanced urothelial cancer following chemotherapy and immunotherapy.
person default
Arjun Balar, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 804 KB
Released: May 4, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bristol-Myers Squibb
Pfizer, Inc. and EMD Serono

Related Content

Downloadable slideset from Eric Jonasch, MD on managing irAEs in patients with advanced RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 16, 2021

Downloadable slideset from Dr Elizabeth R. Plimack on first-line treatment options for patients with RCC, from Clinical Care Options (CCO)

Elizabeth R. Plimack, MD, MS Released: June 16, 2021

Downloadable slideset from Neeraj Agarwal, MD on treatment options for salvage therapy in advanced RCC, from Clinical Care Options (CCO)

Neeraj Agarwal, MD Released: June 16, 2021

Downloadable short slideset from CCO on current treatment recommendations and adverse event management strategies for patients with advanced RCC.

Neeraj Agarwal, MD Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: June 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue